SCT200 + cisplatin + fluorouracil

SCT200 + cisplatin + fluorouracil is a combination regimen consisting of SCT200, a fully humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), combined with cisplatin, a platinum-based chemotherapeutic agent, and fluorouracil, an antimetabolite chemotherapy. SCT200 works by blocking EGFR signaling, thereby inhibiting cancer cell growth and survival[5]. Cisplatin crosslinks DNA, disrupting repair and function, leading to apoptosis in cancer cells[8]. Fluorouracil interferes with DNA synthesis by inhibiting thymidylate synthase, resulting in cell death. This combination is primarily being investigated in advanced solid tumors, including metastatic colorectal cancer, head and neck squamous cell carcinoma, and potentially other cancers resistant to standard therapies[5][1]. SCT200 is developed by Sinocelltech and all three drugs are administered intravenously.

Other names

SCT200SCT-200SCT 200